More recently, another modality of therapy, inhibition of immune checkpoints such as programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) has been also shown to benefit patients with lung cancer. Here, PDCD1 is linked to lung carcinoma.